 random studi effect hydroxychloroquin sulfat system lupu erythematosu canadian hydroxychloroquin studi group background antimalari drug hydroxychloroquin effect manifest system lupu erythematosu effect method six-month double-blind placebo-control studi effect hydroxychloroquin sulfat treatment patient stabl system lupu erythematosu patient dose hydroxychloroquin placebo week patient group prednison result rel risk clinic flare-up develop specif clinic manifest system lupu erythematosu increas sever time percent confid interv patient placebo hydroxychloroquin patient flare-up time flare-up rel risk sever exacerb diseas withdraw studi time percent confid interv patient placebo patient sever exacerb diseas chang dose prednison differ group conclus patient quiescent system lupu erythematosu hydroxychloroquin like clinic flare-up drug